Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans.

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Moderau N, Poyia F, Schwartzberg LS, Tabassum N, Wen J, Krell J, Stebbing J.

Oncotarget. 2018 Feb 24;9(25):17589-17596. doi: 10.18632/oncotarget.24564. eCollection 2018 Apr 3.

2.

Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Belluz LDB, Herzog T, Levitan J, Moderau N, Schwartzberg L, Tabassum N, Wen J, Krell J, Stebbing J.

Oncotarget. 2018 Jan 16;9(10):9456-9467. doi: 10.18632/oncotarget.24258. eCollection 2018 Feb 6. Erratum in: Oncotarget. 2018 Mar 13;9(19):15166.

3.

The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas.

Carter P, Alifrangis C, Chandrasinghe P, Cereser B, Del Bel Belluz L, Leo CA, Moderau N, Tabassum N, Warusavitarne J, Krell J, Stebbing J.

Oncotarget. 2018 Jan 16;9(13):11371-11376. doi: 10.18632/oncotarget.24257. eCollection 2018 Feb 16. Erratum in: Oncotarget. 2018 Mar 13;9(19):15165.

4.

Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.

Carter P, Alifrangis C, Cereser B, Chandrasinghe P, Del Bel Belluz L, Fotopoulou C, Frilling A, Herzog T, Moderau N, Tabassum N, Krell J, Stebbing J.

Oncotarget. 2017 Dec 27;9(5):6007-6014. doi: 10.18632/oncotarget.23675. eCollection 2018 Jan 19. Erratum in: Oncotarget. 2018 Mar 13;9(19):15164.

5.

Impact of molecular profiling on overall survival of patients with advanced ovarian cancer.

Herzog TJ, Spetzler D, Xiao N, Burnett K, Maney T, Voss A, Reddy S, Burger R, Krivak T, Powell M, Friedlander M, McGuire W.

Oncotarget. 2016 Apr 12;7(15):19840-9. doi: 10.18632/oncotarget.7835.

6.

Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments.

Alifrangis C, Carter P, Cereser B, Chandrasinghe P, Belluz LDB, Lim E, Moderau N, Poyia F, Tabassum N, Zhang H, Krell J, Stebbing J.

Oncotarget. 2018 Feb 1;9(16):12805-12811. doi: 10.18632/oncotarget.24375. eCollection 2018 Feb 27.

7.

Biomarkers for personalized oncology: recent advances and future challenges.

Kalia M.

Metabolism. 2015 Mar;64(3 Suppl 1):S16-21. doi: 10.1016/j.metabol.2014.10.027. Epub 2014 Oct 30. Review.

PMID:
25468140
8.

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.

Seeber A, Gastl G, Ensinger C, Spizzo G, Willenbacher W, Kocher F, Leitner C, Willenbacher E, Amann A, Steiner N, Eisterer W, Voss A, Russell K, Zwierzina H.

Genes Cancer. 2016 Sep;7(9-10):301-308. doi: 10.18632/genesandcancer.121.

9.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

PMID:
18705406
10.

Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.

Welt A, Tewes M, Aktas B, O Hoffmann O, Wiesweg M, Ting S, Reis H, Worm K, Richly H, Hense J, Palmer MR, Lee BH, Wendling J, Kossow J, Scheulen ME, Lehnerdt C, Kohl M, Derks C, Skottky S, Haus U, Schmid KW, Kimmig R, Schuler M, Kasper S.

Breast Cancer Res Treat. 2013 Nov;142(1):81-8.

PMID:
24122392
11.

Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.

Chen C, Yuan JP, Wei W, Tu Y, Yao F, Yang XQ, Sun JZ, Sun SR, Li Y.

Int J Nanomedicine. 2014 Feb 21;9:1039-48. doi: 10.2147/IJN.S58270. eCollection 2014.

12.

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G.

Breast Cancer Res. 2009;11(5):R69. doi: 10.1186/bcr2363.

13.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL.

Genome Med. 2016 Oct 25;8(1):109.

14.

Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

Millis SZ, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, O'Shaughnessy JA.

Clin Breast Cancer. 2015 Dec;15(6):473-481.e3. doi: 10.1016/j.clbc.2015.04.008. Epub 2015 Apr 28.

15.

Tumor profiling of gastric and esophageal carcinoma reveal different treatment options.

Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC.

Cancer Biol Ther. 2015;16(5):764-9. doi: 10.1080/15384047.2015.1026479. Epub 2015 Mar 16.

16.

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S.

Cancer Biol Ther. 2015;16(12):1726-37. doi: 10.1080/15384047.2015.1113356.

17.

Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.

Wu YM, Hu W, Wang Y, Wang N, Gao L, Chen ZZ, Zheng WQ.

Breast Cancer Res Treat. 2013 Aug;141(1):23-32. doi: 10.1007/s10549-013-2664-1. Epub 2013 Aug 10.

PMID:
23933801
18.

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, Bazan F, Montcuquet P, Meneveau N, Perrin S, Algros MP, Pivot X.

Oncologist. 2013 Jun;18(6):667-74. doi: 10.1634/theoncologist.2012-0350. Epub 2013 May 30.

19.

Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas.

Smaglo BG, Tesfaye A, Halfdanarson TR, Meyer JE, Wang J, Gatalica Z, Reddy S, Arguello D, Boland PM.

Oncotarget. 2015 Dec 22;6(41):43594-604. doi: 10.18632/oncotarget.6202.

20.

Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.

Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA.

BMC Cancer. 2010 May 21;10:223. doi: 10.1186/1471-2407-10-223.

Supplemental Content

Support Center